Evolving Treatment Strategies for Gallbladder Cancer

被引:184
作者
Hueman, Matthew T. [1 ]
Vollmer, Charles M., Jr. [2 ]
Pawlik, Timothy M. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
POTENTIALLY RESECTABLE TUMORS; ABDOMINAL-WALL METASTASES; FINDING RESIDUAL DISEASE; EXTRAHEPATIC BILE-DUCTS; PORT-SITE METASTASES; LONG-TERM SURVIVAL; LAPAROSCOPIC CHOLECYSTECTOMY; SURGICAL-TREATMENT; RADICAL SURGERY; PRIMARY-CARCINOMA;
D O I
10.1245/s10434-009-0538-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gallbladder cancer is an uncommon cancer that has traditionally been associated with a poor prognosis. In the era of laparoscopic cholecystectomy, incidental gallbladder cancer has dramatically increased and now constitutes the major way patients present with gallbladder cancer. While patients with incidental gallbladder cancer have a better survival than patients with nonincidental gallbladder cancer, incidental gallbladder cancer can be associated with a varied prognosis. Imaging with computed tomography (CT), magnetic resonance imaging (MRI), and [18]F-fluorodeoxyglucose (FDG) positron emission tomography (PET), as well as diagnostic laparoscopy, all have varying roles in the workup of patients with incidental gallbladder cancer. For patients with T1b, T2, and T3 incidental gallbladder cancer re-resection is generally recommended. At re-exploration, many patients with incidental gallbladder cancer will have residual disease. Definitive oncologic management requires re-resection of the liver, portal lymphadenectomy, and attention to the common bile duct. The extent of the hepatic resection should be dictated by the ability to achieve a microscopically negative (R0) margin. Routine resection of the common bile duct is unnecessary but should be undertaken in the setting of a positive cystic duct margin. If an incidental gallbladder cancer is discovered at the time of surgery, whether the surgeon should directly proceed with a more definitive oncologic operation should depend on the surgeon's skill-set and experience. Gallbladder cancer has a propensity to recur. Although data for adjuvant therapy following resection are limited, some data do suggest a survival benefit for adjuvant chemoradiation therapy. Management of patients with gallbladder cancer requires a multidisciplinary approach with input from a surgeon skilled in hepatobiliary surgery.
引用
收藏
页码:2101 / 2115
页数:15
相关论文
共 144 条
[1]  
ALBORESSAAVEDRA J, 1980, CANCER-AM CANCER SOC, V45, P919, DOI 10.1002/1097-0142(19800301)45:5<919::AID-CNCR2820450514>3.0.CO
[2]  
2-4
[3]   Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma [J].
Anderson, CD ;
Rice, MH ;
Pinson, W ;
Chapman, WC ;
Chari, RS ;
Delbeke, D .
JOURNAL OF GASTROINTESTINAL SURGERY, 2004, 8 (01) :90-97
[4]   Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study [J].
Andre, T. ;
Reyes-Vidal, J. M. ;
Fartoux, L. ;
Ross, P. ;
Leslie, M. ;
Rosmorduc, O. ;
Clemens, M. R. ;
Louvet, C. ;
Perez, N. ;
Mehmud, F. ;
Scheithauer, W. .
BRITISH JOURNAL OF CANCER, 2008, 99 (06) :862-867
[5]   Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study [J].
André, T ;
Tournigand, C ;
Rosmorduc, O ;
Provent, S ;
Maindrault-Goebel, F ;
Avenin, D ;
Selle, F ;
Paye, F ;
Hannoun, L ;
Houry, S ;
Gayet, B ;
Lotz, JP ;
de Gramont, A ;
Louvet, C .
ANNALS OF ONCOLOGY, 2004, 15 (09) :1339-1343
[6]   Incidental finding of gallbladder carcinoma detected during or after laparoscopic cholecystectomy [J].
Antonakis, P ;
Alexakis, N ;
Mylonaki, D ;
Leandros, E ;
Konstadoulakis, MM ;
Zografos, G ;
Androulakis, G .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (04) :358-360
[7]  
Aoki Y, 1999, SURGERY, V125, P553, DOI 10.1067/msy.1999.98046
[8]   Post-operative adjuvant radiochemotherapy in the treatment of gallbladder cancer [J].
Baeza, MR ;
Reyes, JM ;
del Castillo, C ;
Rivera, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02) :S285-S286
[9]  
Bartlett DL, 2000, SEMIN SURG ONCOL, V19, P145, DOI 10.1002/1098-2388(200009)19:2<145::AID-SSU7>3.3.CO
[10]  
2-Y